InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-04 | 2026-03-05 | Opaleye Management Inc. | 10% Owner | Sale | 138.3K | $39.67 | $5.49M | 59.4K | View ↗ | |
| 2026-03-03 | 2026-03-05 | Opaleye Management Inc. | 10% Owner | Sale | 60.3K | $39.15 | $2.36M | 63.7K | View ↗ | |
| 2026-02-27 | 2026-03-03 | Opaleye Management Inc. | 10% Owner | Sale | 5,000 | $54.18 | $271K | 65.0K | View ↗ | |
| 2026-01-06 | 2026-01-08 | Opaleye Management Inc. | 10% Owner | Sale | 20.0K | $53.35 | $1.07M | 70.0K | View ↗ | |
| 2025-06-10 | 2025-06-11 | Opaleye Management Inc. | 10% Owner | Sale | 15.0K | $30.80 | $462K | 90.0K | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Total revenues | $394K-60.4% | $995K-92.2% | $12.7M+151.4% | $5.1M |
| Cost of sales | -$67.9M-38.0% | -$49.2M-24.2% | -$39.6M-56.2% | -$25.4M |
| Gross profit | $204.4M+35.9% | $150.4M+66.1% | $90.6M+43.3% | $63.2M |
| Selling, general and administrative | $152.9M+18.5% | $129.1M+55.3% | $83.1M+42.7% | $58.2M |
| Research and development | $20.9M+71.2% | $12.2M+83.9% | $6.7M+118.1% | $3.0M |
| Impairment of long-lived assets | $253K-33.4% | $380K | — | — |
| Total operating expenses | $173.9M+22.8% | $141.5M+57.1% | $90.1M+47.0% | $61.3M |
| Income from operations | $30.5M+245.9% | $8.8M+1946.9% | $431K-77.5% | $1.9M |
| Interest expense, net | -$24.2M-6.1% | -$22.8M-6.9% | -$21.3M-194.4% | -$7.2M |
| Investment (loss) gain from Eton Pharmaceuticals | -$3.2M-202.6% | $3.1M | — | — |
| Loss on extinguishment of debt | -$7.8M-41.8% | -$5.5M | — | — |
| Other income (expense), net | $47K+125.4% | -$185K+58.3% | -$444K | — |
| Total other expense, net | -$31.9M-22.0% | -$26.1M-8.3% | -$24.1M-51.5% | -$15.9M |
| Loss before income taxes | -$1.4M+92.1% | -$17.3M+27.0% | -$23.7M | — |
| Income tax expense | -$3.8M-2242.2% | -$161K+77.0% | -$701K | — |
| Net loss | -$5.1M+70.6% | -$17.5M+28.4% | -$24.4M | — |
| Basic net loss per share of common stock | -$0.14+71.4% | -$0.49+34.7% | -$0.75-47.1% | -$0.51 |
| Diluted net loss per share of common stock | -$0.14+71.4% | -$0.49+34.7% | -$0.75-47.1% | -$0.51 |
| Weighted average number of shares of common stock outstanding, basic | $36.8M+3.1% | $35.7M+9.3% | $32.6M+18.8% | $27.5M |
| Weighted average number of shares of common stock outstanding, diluted | $36.8M+3.1% | $35.7M+9.3% | $32.6M+18.8% | $27.5M |
| Product Sales Net [Member] | ||||
| Total revenues | $394K-60.4% | $995K-92.2% | $12.7M+151.4% | $5.1M |
| Other Revenues [Member] | ||||
| Total revenues | $394K-60.4% | $995K-92.2% | $12.7M+151.4% | $5.1M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Relay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Lags Revenue Estimates
Analysts Estimate Harrow (HROW) to Report a Decline in Earnings: What to Look Out for
Is Harrow, Inc. (HROW) A Good Stock To Buy Now?
Harrow To Report First Quarter 2026 Financial Results After Market Close on May 11, 2026